EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.340
https://www.valueinhealthjournal.com/article/S1098-3015(23)03470-8/fulltext
Title :
EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03470-8&doi=10.1016/j.jval.2023.09.340
First page :
Section Title :
Open access? :
No
Section Order :
12364